 |
|
 |
|
MPI-P The Max Planck Institute for Polymer Research (MPI-P) was founded in 1983 on the campus of the Johannes Gutenberg University and commenced work in June 1984. Dr. Tanja Weil is the Director of the “Synthesis of Macromolecules” department at MPI-P, that aims to develop nanomaterials for biomedical science applications.
IMM The Instituto de Medicina Molecular is a non-profit, private research organization and one of the leading biomedical research institutions in Portugal and Europe. The mission of IMM is to foster basic, clinical and translational biomedical research. Leading References: 1. Ferreira MC et al.; Bernardes GJL Angew Chem Int Ed 2015, 54, 1172-1175.
FFUL FFUL is a research-oriented institution in Pharmaceutical Sciences. Raking first among the Schools of Pharmacy in Portugal, it provides PhD and master programs aimed at both scientific and professional training of excellence. FFUL host the iMed.ULisboa, a multidisciplinary R&D Unit in Life and Health Sciences, whose mission is to develop novel therapies and benefit human health through top class research. Leading References: 1. Cal PMSD et al.; Gois PMP Chem. Eur. J. 2015, 21, 8182.
UCL Department of Chemistry is one of the top Chemistry departments in the UK with a 5** rating. The Organic Chemistry and Chemical Biology section comprises 16 academic staff engaged in a variety of research activities that are underpinned by organic synthesis including the development of new reaction methodologies and catalysts, target asymmetric synthesis of molecules with profound biological activity, through to peptide, protein and DNA chemistry, radiochemistry and molecule imaging, single molecule detection, mass spectrometry, bionanotechnology, biocatalysis, chemical genetics and directed evolution. In much of this work interactions with biology and medicine is vital and a number of exciting projects are developing new therapeutics for treatment of a variety of diseases such as cancer or cardiovascular disease. Activities in the areas of Chemical Biology and Medicinal Chemistry are coordinated through the Centre for Chemical Biology. Leading References: 1. Chudasama V; Caddick S et al. Chem Commun 2015, Accepted.
Prof. Tanja Weil – UULM Ulm University (UULM) is a public university that was funded in 1967. UULM has been ranked at position no. 16 among word’s top 100 universities under the age of 50 in 2014 thus making it the best young university in Germany. It also frequently ranks as one of the top schools in natural sciences in domestic rankings. Leading References: 1. Ng D Y W, Weil T et al. Angew. Chem. Int. Ed. 2014, 53, 324.
Dr. Francisco Corzana – Uni. La Rioja The University of La Rioja (UR) is a public institution of higher education based in Logroño, Spain. Inaugurated during 1992-1993 from various existing schools and colleges, it currently teaches Grades 19 adapted to the European Higher Education, and a varied program of masters and summer courses. It has earned the Campus International Excellence for the project "Iberus" presented together with the public universities of Zaragoza, Navarra and Lledia. Students enjoy a personalized learning system that has integrated new technologies with small groups and a personal tutor. The staff at the University of La Rioja is composed of about 450 members of teaching and research staff and 250 other members of the Administration and Services. The ratio remains at 15 students per teacher. The UR is part of Group 9 of Universities, which brings together the nine public campuses that are unique in their autonomous region. Dr. Corzana is an Associate Professor at the Department of Chemistry. He is a specialist in peptide and glycopeptide synthesis as well as in conformational analysis of these compounds by NMR and molecular modelling. Dr. Corzana has more than 60 publications and about 20 invited lectures at international meetings. Leading References: 1. Angew. Chem. Int. Ed. 2013, 52, 3848-3151.
Dr Tuomas Knowles – Uni. Cambridge Cambridge University is one of the premier universities in the world. The Chemistry Department has received top 5* rating in the 1996 and 2001 UK Research Assessment Exercises, has an international reputation of excellence, and has ten research-active Fellows of the Royal Society. Fifty research groups covering a vast range of Chemistry are supported by almost 100 technical, computing and clerical staff. There are over 150 postdocs and 250 graduate students engaged in full time research. The Department is also responsible for over 350 publications annually across the whole spectrum of chemical science, and it has created numerous spin-off companies. The Department may well have hosted more EU Human Capital and Mobility or Marie Curie fellows than any other Department in Europe. We have also been members of a vast number of EU training networks. Cambridge University and the Chemistry Department provide a full programme of lectures, seminars, and training activities, backed up by a mentoring scheme for students and an appraisal scheme for postdocs. Dr Tuomas Knowles is a University Reader in Physical Chemistry. His work in Cambridge is centred around the study of the physicochemical properties and behaviour of biological molecules and soft materials. He is the recipient of a number of prizes including the 2012 Royal Society of Chemistry and an ERC starter grant. He has published 72 papers. Leading References: 1. Shimanovich U et al.; Knowles TPJ ACS Nano 2015, in press.
Dr Ludger Johannes – Institut Curie Institut Curie (IC) is a modern research centre whose medical activities are entirely dedicated to the treatment of cancer. The main strength of IC is the active collaboration between its world-class Cell Biology and Physics Departments, with strong links to chemistry. Dr Ludger Johannes is Research Director (INSERM, equivalent to full Professor) in Cell Biology. He directs the Chemical Biology CNRS-INSERM unit at the Curie Institute. With Frédéric Schmidt's team from the chemistry section of the unit, he aims at establishing fundamental concepts of endocytosis and intracellular trafficking, and at exploiting these discoveries in fundamental membrane biology for the development of innovative cancer therapy strategies. He is inventor on 9 patent families, founder of 2 biotech companies, and EMBO member since 2012. The results of his group have been published in several high-ranking journals. 1. Renard HF et al.; Johannes L Nature 2015, Accepted.
Prof Christian Becker – UniVie At the Institute of Biological Chemistry chemical approaches, such as solid phase peptide synthesis, are combined with biotechnological approaches in order to produce site-specifically modified proteins. Linking synthetic peptides and expressed proteins becomes possible through chemoselective ligation reactions and provides access to proteins with tailor-made properties. These proteins help to answer remaining biological questions regarding folding, enzymatic activity and protein-protein interactions in vitro and in vivo as well as addressing biomedicinal aspects such as delivery of peptide and protein drugs. 1. Lechner CC; Becker CF Biomater Sci 2014, in press.
PharmaMar (www.pharmamar.com), a wholly owned member of the Zeltia Group, is a biopharmaceutical company determined to advance cancer treatment through discovering, developing, producing, and marketing innovative drugs of marine origin. PM has a unique marine organism library containing over 140,000 specimens. PharmaMar’s Research, Development, and Innovation Department has discovered 700 new chemical entities and identified more than 30 new families of compounds. As a result of this work, PharmaMar has over 1800 patents that either have been awarded or are in the processing stage. Yondelis®, developed by PharmaMar and approved by the European Commission in 2007 for the treatment of Soft Tissue Sarcoma, and in 2009 for the treatment of Relapsed Ovarian Cancer, is the first in a new generation of antitumour drugs developed from marine compounds. PharmaMar has four other pipeline compounds, Aplidin®, Zalypsis®, PM01183 and PM060184 in different phases of clinical evaluation. PharmaMar ranks among the leading Spanish pharmaceutical companies that invest heavily in Research, Development, and Innovation. The company has a workforce of 300 highly qualified professionals who specialize in the pharmaceutical sector.
Hovione (www.hovione.com) is a global company with over 50 years’ experience in API and Drug Product Intermediate development and compliant manufacture. Hovione offers integrated API, innovative particle engineering technologies, formulation development and manufacturing for both oral and non-oral dosage forms. Hovione has generated revenues of $201 million (FY2013) and employs over 1250 people, 168 of which in R&D, across its industrial presence in the US, Ireland, China and Portugal.
|
|
